{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:50:43Z","timestamp":1792785043496,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":125,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Innovation Project of Guangxi Graduate Education","award":["JGY2023073"],"award-info":[{"award-number":["JGY2023073"]}]},{"name":"the Guangxi Key Research and Development Plan","award":["GuiKe AB25069099; GuiKe AB24010082"],"award-info":[{"award-number":["GuiKe AB25069099; GuiKe AB24010082"]}]},{"DOI":"10.13039\/501100017691","name":"Guangxi Key Research and Development Program","doi-asserted-by":"publisher","award":["AB25069008"],"award-info":[{"award-number":["AB25069008"]}],"id":[{"id":"10.13039\/501100017691","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Clinical Discipline Construction Project of Guangxi Medical University","award":["GXMULJZ202403"],"award-info":[{"award-number":["GXMULJZ202403"]}],"id":[{"id":"https:\/\/ror.org\/03dveyr97","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-53344-3","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T22:38:51Z","timestamp":1780439931000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Progression-free survival as a potential surrogate endpoint for overall survival after conversion therapy for unresectable hepatocellular carcinoma (GUIDANCE008)"],"prefix":"10.1038","volume":"16","author":[{"given":"Jin-Wei","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da-Long","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Chang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mian-Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Rong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Yao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Bing","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Sheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Liang","family":"Nong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Qun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuang","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-He","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan-Jian","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-Ping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Song","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Quan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Cheng","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Feng","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teng-Meng","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Qing","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-Qun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1494-6396","authenticated-orcid":false,"given":"Jian-Hong","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6541-4007","authenticated-orcid":false,"given":"Ping","family":"Cen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The GUIDANCE investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Hong","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bang-De","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da-Long","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-Qun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Qun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Qun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-Ping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuang","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Jun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Liang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Liang","family":"Nong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-He","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Feng","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Yu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Jie","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Chang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying Xue","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Bing","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Yao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan-Jian","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mian-Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Sheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Rong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao-Zhi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Cheng","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Song","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Feng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-Man","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Quan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Yin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teng-Meng","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian-Shuang","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teng-Xian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang-Cai","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao-Ming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Dong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Qing","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Kai","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Cong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Hai","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian-Jian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-Hong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Yuan","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Cheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Quan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Wei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Cen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"issue":"1","key":"53344_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA Cancer J. Clin. 74(1), 12\u201349 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"53344_CR2","first-page":"9","volume":"11","author":"L Lani","year":"2025","unstructured":"Lani, L., Zaccherini, G., Giannini, E. G. & Trevisani, F. Surveillance for patients at risk of hepatocellular carcinoma: How to improve its cost-effectiveness and expand the role of multidisciplinary tumor board?. Hepatoma Res. 11, 9 (2025).","journal-title":"Hepatoma Res."},{"issue":"9","key":"53344_CR3","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1111\/liv.12818","volume":"35","author":"JW Park","year":"2015","unstructured":"Park, J. W. et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: The BRIDGE Study. Liver Int. 35(9), 2155\u20132166 (2015).","journal-title":"Liver Int."},{"issue":"2","key":"53344_CR4","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1097\/SLA.0000000000000236","volume":"260","author":"JH Zhong","year":"2014","unstructured":"Zhong, J. H. et al. Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma. Ann. Surg. 260(2), 329\u2013340 (2014).","journal-title":"Ann. Surg."},{"issue":"7","key":"53344_CR5","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s12094-017-1621-6","volume":"19","author":"X Xiang","year":"2017","unstructured":"Xiang, X. et al. Distribution of tumor stage and initial treatment modality in patients with primary hepatocellular carcinoma. Clin. Transl. Oncol. 19(7), 891\u2013897 (2017).","journal-title":"Clin. Transl. Oncol."},{"issue":"6","key":"53344_CR6","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","volume":"78","author":"AG Singal","year":"2023","unstructured":"Singal, A. G. et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology 78(6), 1922\u20131965 (2023).","journal-title":"Hepatology"},{"issue":"1","key":"53344_CR7","doi-asserted-by":"publisher","first-page":"100145","DOI":"10.1016\/j.iliver.2025.100145","volume":"4","author":"JM Wang","year":"2025","unstructured":"Wang, J. M. et al. Treatment for unresectable hepatocellular carcinoma patients: Options and management after complete response. Iliver 4(1), 100145 (2025).","journal-title":"Iliver"},{"key":"53344_CR8","doi-asserted-by":"crossref","unstructured":"Li, J., Liang, Y. B., Wang, Q. B. et al. Rechallenge with immune checkpoint inhibitors in patients with hepatocellular carcinoma: A narrative review. Liver Cancer Oct 31 (2025). doi: 10.1159\/000549355.","DOI":"10.1159\/000549355"},{"issue":"5","key":"53344_CR9","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1159\/000544981","volume":"14","author":"M Kudo","year":"2025","unstructured":"Kudo, M. et al. Depth and duration of response are associated with survival in patients with unresectable hepatocellular carcinoma: exploratory analyses of IMbrave150. Liver Cancer 14(5), 539\u2013554 (2025).","journal-title":"Liver Cancer"},{"key":"53344_CR10","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1097\/HEP.0000000000001229","volume":"82","author":"DL Yang","year":"2025","unstructured":"Yang, D. L. et al. Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages. Hepatology 82, 357\u2013369 (2025).","journal-title":"Hepatology"},{"issue":"10474","key":"53344_CR11","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(24)02575-3","volume":"405","author":"M Kudo","year":"2025","unstructured":"Kudo, M. et al. Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): A multicentre, randomised, double-blind, phase 3 study. Lancet 405(10474), 203\u2013215 (2025).","journal-title":"Lancet"},{"issue":"10474","key":"53344_CR12","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S0140-6736(24)02551-0","volume":"405","author":"B Sangro","year":"2025","unstructured":"Sangro, B. et al. Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): A multiregional, randomised, double-blind, placebo-controlled, phase 3 study. Lancet 405(10474), 216\u2013232 (2025).","journal-title":"Lancet"},{"issue":"4","key":"53344_CR13","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1159\/000543994","volume":"14","author":"M Piao","year":"2025","unstructured":"Piao, M. et al. Conversion surgery after immune checkpoint inhibitor-based combination therapy for initially unresectable hepatocellular carcinoma: A retrospective cohort study. Liver Cancer 14(4), 456\u2013473 (2025).","journal-title":"Liver Cancer"},{"issue":"5","key":"53344_CR14","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1159\/000536376","volume":"13","author":"ZX Zeng","year":"2024","unstructured":"Zeng, Z. X. et al. Prognostic value of pathological response for patients with unresectable hepatocellular carcinoma undergoing conversion surgery. Liver Cancer 13(5), 498\u2013508 (2024).","journal-title":"Liver Cancer"},{"issue":"10","key":"53344_CR15","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1111\/apt.18237","volume":"60","author":"T Hatanaka","year":"2024","unstructured":"Hatanaka, T. et al. Predictive factors and survival outcome of conversion therapy for unresectable hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: Comparative analysis of conversion, partial response and complete response patients. Aliment Pharmacol. Ther. 60(10), 1361\u20131373 (2024).","journal-title":"Aliment Pharmacol. Ther."},{"issue":"6","key":"53344_CR16","doi-asserted-by":"publisher","first-page":"505","DOI":"10.5582\/bst.2024.01394","volume":"18","author":"H Tang","year":"2025","unstructured":"Tang, H. et al. Chinese expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition). Biosci. Trends 18(6), 505\u2013524 (2025).","journal-title":"Biosci. Trends"},{"issue":"7","key":"53344_CR17","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1093\/bjs\/znad127","volume":"110","author":"K Kataoka","year":"2023","unstructured":"Kataoka, K. et al. Correlation between recurrence-free survival and overall survival after upfront surgery for resected colorectal liver metastases. Br. J. Surg. 110(7), 864\u2013869 (2023).","journal-title":"Br. J. Surg."},{"issue":"2","key":"53344_CR18","doi-asserted-by":"publisher","first-page":"znae038","DOI":"10.1093\/bjs\/znae038","volume":"111","author":"J Okui","year":"2024","unstructured":"Okui, J. et al. Recurrence-free survival as a surrogate endpoint for overall survival after neoadjuvant chemotherapy and surgery for oesophageal squamous cell carcinoma. Br. J. Surg. 111(2), znae038 (2024).","journal-title":"Br. J. Surg."},{"issue":"16","key":"53344_CR19","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1200\/JCO.22.02363","volume":"41","author":"P Squifflet","year":"2023","unstructured":"Squifflet, P. et al. Re-evaluation of pathologic complete response as a surrogate for event-free and overall survival in human epidermal growth factor receptor 2-positive, early breast cancer treated with neoadjuvant therapy including anti-human epidermal growth factor receptor 2 therapy. J. Clin. Oncol. 41(16), 2988\u20132997 (2023).","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"53344_CR20","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1093\/jnci\/djt269","volume":"105","author":"X Paoletti","year":"2013","unstructured":"Paoletti, X. et al. Progression-free survival as a surrogate for overall survival in advanced\/recurrent gastric cancer trials: A meta-analysis. J. Natl. Cancer Inst. 105(21), 1667\u20131670 (2013).","journal-title":"J. Natl. Cancer Inst."},{"issue":"1","key":"53344_CR21","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1200\/JCO.2014.56.5887","volume":"33","author":"Q Shi","year":"2015","unstructured":"Shi, Q. et al. Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: Findings from the analysis and research in cancers of the digestive system database. J. Clin. Oncol. 33(1), 22\u201328 (2015).","journal-title":"J. Clin. Oncol."},{"key":"53344_CR22","doi-asserted-by":"publisher","DOI":"10.1159\/000548606","author":"S Yacob","year":"2025","unstructured":"Yacob, S. et al. Surrogate endpoints for overall survival in advanced hepatocelluar carcinoma in the era of immunotherapy: A trial level meta-analysis. Liver Cancer https:\/\/doi.org\/10.1159\/000548606 (2025).","journal-title":"Liver Cancer"},{"issue":"1","key":"53344_CR23","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s43856-025-01303-w","volume":"6","author":"DL Yang","year":"2026","unstructured":"Yang, D. L. et al. Neoadjuvant transarterial chemoembolization with tyrosine kinase and immune checkpoint inhibitors improves survival from resectable hepatocellular carcinoma in a multicenter, retrospective study (GUIDANCE002). Commun. Med. 6(1), 139 (2026).","journal-title":"Commun. Med."},{"issue":"6","key":"53344_CR24","first-page":"687","volume":"14","author":"DL Yang","year":"2025","unstructured":"Yang, D. L. et al. Survival benefit of hepatectomy after complete or partial response to conversion therapy in unresectable hepatocellular carcinoma (GUIDANCE003): A multicenter study. Liver Cancer 14(6), 687\u2013703 (2025).","journal-title":"Liver Cancer"},{"issue":"11","key":"53344_CR25","doi-asserted-by":"publisher","first-page":"101587","DOI":"10.1016\/j.jhepr.2025.101587","volume":"7","author":"DL Yang","year":"2025","unstructured":"Yang, D. L. et al. Prognostic value of radiological and pathological complete response following immune-based conversion therapy in patients with unresectable hepatocellular carcinoma (GUIDANCE004). JHEP Rep. 7(11), 101587 (2025).","journal-title":"JHEP Rep."},{"key":"53344_CR26","doi-asserted-by":"crossref","unstructured":"Ma, L., Yang, D. L., Zhong, T. M. et al. Prognostic usefulness of clinical complete response after PD-1 inhibitor-based combination therapy for unresectable hepatocellular carcinoma (GUIDANCE006). Liver Cancer  2025 Dec 1 (2025). doi: 10.1159\/000549844.","DOI":"10.1159\/000551852"},{"key":"53344_CR27","doi-asserted-by":"crossref","unstructured":"World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA 310(20), 2191\u20132194 (2013).","DOI":"10.1001\/jama.2013.281053"},{"issue":"3","key":"53344_CR28","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1159\/000488035","volume":"7","author":"J Zhou","year":"2018","unstructured":"Zhou, J. et al. Guidelines for diagnosis and treatment of primary liver cancer in China (2017 edition). Liver Cancer 7(3), 235\u2013260 (2018).","journal-title":"Liver Cancer"},{"issue":"4","key":"53344_CR29","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.ejca.2012.08.022","volume":"49","author":"BK Kim","year":"2013","unstructured":"Kim, B. K. et al. Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation. Eur. J. Cancer 49(4), 826\u2013834 (2013).","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"53344_CR30","first-page":"0","volume":"13","author":"K Akahoshi","year":"2024","unstructured":"Akahoshi, K. et al. Oncological resectability criteria for hepatocellular carcinoma in the era of novel systemic therapies: The Japan Liver Cancer Association and Japanese Society of Hepato-Biliary-Pancreatic Surgery expert consensus statement 2023. Liver Cancer 13(6), 0\u201310 (2024).","journal-title":"Liver Cancer"},{"issue":"6","key":"53344_CR31","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1159\/000509424","volume":"9","author":"J Zhou","year":"2020","unstructured":"Zhou, J. et al. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 edition). Liver Cancer 9(6), 682\u2013720 (2020).","journal-title":"Liver Cancer"},{"issue":"5","key":"53344_CR32","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1159\/000530495","volume":"12","author":"J Zhou","year":"2023","unstructured":"Zhou, J. et al. Guidelines for the diagnosis and treatment of primary liver cancer (2022 edition). Liver Cancer 12(5), 405\u2013444 (2023).","journal-title":"Liver Cancer"},{"issue":"1","key":"53344_CR33","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/bjs\/znab340","volume":"109","author":"JH Zhong","year":"2021","unstructured":"Zhong, J. H. et al. Repeat hepatic resection versus radiofrequency ablation for recurrent hepatocellular carcinoma: Retrospective multicentre study. Br. J. Surg. 109(1), 71\u201378 (2021).","journal-title":"Br. J. Surg."},{"issue":"2","key":"53344_CR34","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur. J. Cancer 45(2), 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"53344_CR35","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.annonc.2025.02.006","volume":"36","author":"A Vogel","year":"2025","unstructured":"Vogel, A. et al. Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 36(5), 491\u2013506 (2025).","journal-title":"Ann. Oncol."},{"issue":"27","key":"53344_CR36","doi-asserted-by":"publisher","first-page":"4781","DOI":"10.1002\/sim.5874","volume":"32","author":"M Schemper","year":"2013","unstructured":"Schemper, M., Kaider, A., Wakounig, S. & Heinze, G. Estimating the correlation of bivariate failure times under censoring. Stat. Med. 32(27), 4781\u20134790 (2013).","journal-title":"Stat. Med."},{"key":"53344_CR37","unstructured":"Validity of surrogate endpoints in oncology: Executive summary of rapid report A10-05, Version 1.1. Institute for Quality and Efficiency in Health Care: Executive Summaries (Institute for Quality and Efficiency in Health Care (IQWiG))."},{"issue":"8","key":"53344_CR38","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1001\/jamainternmed.2015.2829","volume":"175","author":"V Prasad","year":"2015","unstructured":"Prasad, V., Kim, C., Burotto, M. & Vandross, A. The strength of association between surrogate end points and survival in oncology: A systematic review of trial-level meta-analyses. JAMA Intern. Med. 175(8), 1389\u20131398 (2015).","journal-title":"JAMA Intern. Med."},{"issue":"10","key":"53344_CR39","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/S1470-2045(22)00506-X","volume":"23","author":"BL Ecker","year":"2022","unstructured":"Ecker, B. L. et al. Recurrence-free survival versus overall survival as a primary endpoint for studies of resected colorectal liver metastasis: A retrospective study and meta-analysis. Lancet Oncol. 23(10), 1332\u20131342 (2022).","journal-title":"Lancet Oncol."},{"issue":"34","key":"53344_CR40","doi-asserted-by":"publisher","first-page":"8664","DOI":"10.1200\/JCO.2005.01.6071","volume":"23","author":"DJ Sargent","year":"2005","unstructured":"Sargent, D. J. et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: Individual patient data from 20,898 patients on 18 randomized trials. J. Clin. Oncol. 23(34), 8664\u20138670 (2005).","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"53344_CR41","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13027-024-00575-6","volume":"19","author":"DL Yang","year":"2024","unstructured":"Yang, D. L. et al. Prevalence of metabolic syndrome among patients with hepatocellular carcinoma of different etiologies: A retrospective study. Infect. Agent Cancer 19(1), 21 (2024).","journal-title":"Infect. Agent Cancer"},{"issue":"11","key":"53344_CR42","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1001\/jamaoncol.2024.4085","volume":"10","author":"CL Chiang","year":"2024","unstructured":"Chiang, C. L. et al. Complete response to locoregional therapy plus immunotherapy for hepatocellular carcinoma. JAMA Oncol. 10(11), 1548\u20131553 (2024).","journal-title":"JAMA Oncol."},{"issue":"11","key":"53344_CR43","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/S1470-2045(24)00457-1","volume":"25","author":"A D'Alessio","year":"2024","unstructured":"D\u2019Alessio, A. et al. Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: A cross-trial, patient-level analysis. Lancet Oncol. 25(11), 1465\u20131475 (2024).","journal-title":"Lancet Oncol."},{"issue":"2","key":"53344_CR44","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1097\/JS9.0000000000000942","volume":"110","author":"Z Hu","year":"2024","unstructured":"Hu, Z. et al. Survival benefit of liver resection following complete response to transarterial chemoembolization for intermediate-stage hepatocellular carcinoma: A retrospective, multicenter, cohort study. Int. J. Surg. 110(2), 1019\u20131027 (2024).","journal-title":"Int. J. Surg."},{"issue":"10415","key":"53344_CR45","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/S0140-6736(23)01796-8","volume":"402","author":"S Qin","year":"2023","unstructured":"Qin, S. et al. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): A randomised, open-label, multicentre, phase 3 trial. Lancet 402(10415), 1835\u20131847 (2023).","journal-title":"Lancet"},{"issue":"10","key":"53344_CR46","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s00535-023-02018-2","volume":"58","author":"L Li","year":"2023","unstructured":"Li, L. et al. Adjuvant immune checkpoint inhibitors associated with higher recurrence-free survival in postoperative hepatocellular carcinoma (PREVENT): A prospective, multicentric cohort study. J. Gastroenterol. 58(10), 1043\u20131054 (2023).","journal-title":"J. Gastroenterol."},{"issue":"6","key":"53344_CR47","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.jhep.2019.01.028","volume":"70","author":"JM Llovet","year":"2019","unstructured":"Llovet, J. M., Montal, R. & Villanueva, A. Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival. J. Hepatol. 70(6), 1262\u20131277 (2019).","journal-title":"J. Hepatol."},{"issue":"23","key":"53344_CR48","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","volume":"15","author":"JD Wolchok","year":"2009","unstructured":"Wolchok, J. D. et al. Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin. Cancer Res. 15(23), 7412\u20137420 (2009).","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"53344_CR49","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1016\/j.ejso.2017.06.017","volume":"43","author":"K Kataoka","year":"2017","unstructured":"Kataoka, K. et al. Surrogacy of progression-free survival (PFS) for overall survival (OS) in esophageal cancer trials with preoperative therapy: Literature-based meta-analysis. Eur. J. Surg. Oncol. 43(10), 1956\u20131961 (2017).","journal-title":"Eur. J. Surg. Oncol."},{"issue":"12","key":"53344_CR50","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1200\/JCO.2007.10.8407","volume":"26","author":"T Burzykowski","year":"2008","unstructured":"Burzykowski, T. et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J. Clin. Oncol. 26(12), 1987\u20131992 (2008).","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"53344_CR51","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1200\/JCO.24.00337","volume":"43","author":"T Macarulla","year":"2024","unstructured":"Macarulla, T. et al. Atezolizumab plus chemotherapy with or without bevacizumab in advanced biliary tract cancer: Clinical and biomarker data from the randomized phase II IMbrave151 trial. J. Clin. Oncol. 43(5), 545\u2013557 (2024).","journal-title":"J. Clin. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53344-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53344-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53344-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:05:01Z","timestamp":1791245101000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53344-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["53344"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-53344-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"assertion":[{"value":"16 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The ethics committees at the lead sites (Guangxi Medical University Cancer Hospital and the Fourth People\u2019s Hospital of Nanning) waived the requirement for informed consent because the study was retrospective, the data were anonymized, and obtaining individual consent was impracticable. The data for this retrospective, multicenter observational study was sourced from 20 hospitals in China. These hospitals were identified by the prospective database of the regional registry \u201cGuangxi Liver Cancer Clinical Study Alliance (GUIDANCE)\u201d curated by the Liver Cancer Committee of the Guangxi Anticancer Association. This retrospective study received ethical approval from the 20 participating medical centers in China, with Guangxi Medical University Cancer Hospital (approval KY2024386) and the Fourth People\u2019s Hospital of Nanning serving as the lead sites (approval [2026]05), and was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"30975"}}